| Active substance | glofitamab |
| Holder | Nv Roche sa |
| Status | closed |
| Indication | In combination with gemcitabine and oxaliplatin for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT). |
| Public documents | |
| Informed consent | |
| Last update | 08/01/2026 |